Gufic Biosciences Limited (GUFICBIO.NS)
INR 316.35
(2.03%)
INR 316.35
(2.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.19 Billion INR | 4.53% |
| 2022 | 3.05 Billion INR | 479.0% |
| 2021 | 527.79 Million INR | -4.62% |
| 2020 | 553.35 Million INR | -52.37% |
| 2019 | 1.16 Billion INR | 23.43% |
| 2018 | 941.24 Million INR | 23.89% |
| 2017 | 759.77 Million INR | 40.87% |
| 2016 | 539.33 Million INR | 40.18% |
| 2015 | 384.74 Million INR | 37.1% |
| 2014 | 280.63 Million INR | -11.59% |
| 2013 | 317.41 Million INR | -7.36% |
| 2012 | 342.64 Million INR | 83.48% |
| 2011 | 186.75 Million INR | -6.23% |
| 2010 | 199.15 Million INR | 21.2% |
| 2009 | 164.32 Million INR | 12.15% |
| 2008 | 146.51 Million INR | -2.35% |
| 2007 | 150.04 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 3.54 Billion INR | 1139.11% |
| 2023 FY | 3.19 Billion INR | 4.53% |
| 2023 Q4 | 3.19 Billion INR | 1857.61% |
| 2023 Q3 | 163.17 Million INR | -95.4% |
| 2023 Q1 | 286.01 Million INR | -90.64% |
| 2022 Q4 | 3.05 Billion INR | 560.5% |
| 2022 FY | 3.05 Billion INR | 479.0% |
| 2022 Q2 | 1.55 Billion INR | 1243.61% |
| 2022 Q1 | 116.08 Million INR | -78.01% |
| 2022 Q3 | 462.66 Million INR | -70.34% |
| 2021 Q1 | 131.77 Million INR | -76.19% |
| 2021 FY | 527.79 Million INR | -4.62% |
| 2021 Q2 | 235.68 Million INR | 78.85% |
| 2021 Q3 | 729.68 Million INR | 209.6% |
| 2021 Q4 | 527.79 Million INR | -27.67% |
| 2020 Q2 | 1.23 Billion INR | 1041.53% |
| 2020 Q1 | 108.17 Million INR | -90.69% |
| 2020 FY | 553.35 Million INR | -52.37% |
| 2020 Q3 | 113.44 Million INR | -90.81% |
| 2020 Q4 | 553.35 Million INR | 387.77% |
| 2019 Q3 | 82.29 Million INR | -92.48% |
| 2019 FY | 1.16 Billion INR | 23.43% |
| 2019 Q1 | 75.94 Million INR | -91.93% |
| 2019 Q2 | 1.09 Billion INR | 1340.95% |
| 2019 Q4 | 1.16 Billion INR | 1311.81% |
| 2018 Q4 | 941.24 Million INR | 152.96% |
| 2018 Q3 | 372.08 Million INR | -58.41% |
| 2018 Q2 | 894.69 Million INR | 732.12% |
| 2018 FY | 941.24 Million INR | 23.89% |
| 2018 Q1 | 107.52 Million INR | -85.85% |
| 2017 Q1 | 55.25 Million INR | -89.75% |
| 2017 FY | 759.77 Million INR | 40.87% |
| 2017 Q4 | 759.77 Million INR | 227.69% |
| 2017 Q3 | 231.85 Million INR | -68.65% |
| 2017 Q2 | 739.63 Million INR | 1238.48% |
| 2016 Q2 | 381.9 Million INR | 520.09% |
| 2016 Q3 | 38.96 Million INR | -89.8% |
| 2016 FY | 539.33 Million INR | 40.18% |
| 2016 Q4 | 539.33 Million INR | 1284.02% |
| 2016 Q1 | 61.58 Million INR | -83.99% |
| 2015 Q3 | 56.46 Million INR | -80.94% |
| 2015 Q1 | 62.06 Million INR | -77.89% |
| 2015 FY | 384.74 Million INR | 37.1% |
| 2015 Q4 | 384.74 Million INR | 581.42% |
| 2015 Q2 | 296.2 Million INR | 377.26% |
| 2014 Q3 | 21.18 Million INR | -91.67% |
| 2014 Q2 | 254.48 Million INR | 901.35% |
| 2014 FY | 280.63 Million INR | -11.59% |
| 2014 Q1 | 25.41 Million INR | -91.99% |
| 2014 Q4 | 280.63 Million INR | 1224.64% |
| 2013 Q1 | 12.78 Million INR | -96.27% |
| 2013 Q2 | 312.38 Million INR | 2343.78% |
| 2013 Q3 | 13.95 Million INR | -95.53% |
| 2013 Q4 | 317.41 Million INR | 2174.38% |
| 2013 FY | 317.41 Million INR | -7.36% |
| 2012 FY | 342.64 Million INR | 83.48% |
| 2012 Q4 | 342.64 Million INR | 0.0% |
| 2012 Q3 | - INR | 100.0% |
| 2012 Q2 | -14.46 Million INR | 0.0% |
| 2011 FY | 186.75 Million INR | -6.23% |
| 2011 Q4 | 186.75 Million INR | 0.0% |
| 2010 FY | 199.15 Million INR | 21.2% |
| 2009 FY | 164.32 Million INR | 12.15% |
| 2008 FY | 146.51 Million INR | -2.35% |
| 2007 FY | 150.04 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aarti Drugs Limited | 5.54 Billion INR | 42.428% |
| Albert David Limited | -278.36 Million INR | 1247.512% |
| Alembic Limited | 66.9 Million INR | -4674.764% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 17417.126% |
| Hester Biosciences Limited | 2.29 Billion INR | -39.445% |
| Hikal Limited | 7.96 Billion INR | 59.906% |
| Ind-Swift Limited | 9.5 Billion INR | 66.406% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -2561.066% |
| Unichem Laboratories Limited | 931.91 Million INR | -242.769% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 17.372% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -1289.238% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 3.172% |
| Brooks Laboratories Limited | 49.48 Million INR | -6355.122% |
| Eris Lifesciences Limited | 13.8 Billion INR | 76.863% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 68.158% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 329.819% |
| Wanbury Limited | 1.1 Billion INR | -188.85% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -22.299% |
| Alkem Laboratories Limited | -1.6 Billion INR | 298.479% |
| FDC Limited | -57.75 Million INR | 5631.093% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 212.371% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 176.915% |
| Innova Captab Limited | 2.33 Billion INR | -36.874% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 390.05% |
| Ipca Laboratories Limited | 11.41 Billion INR | 72.017% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 88.201% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 2602.638% |
| Lupin Limited | 19.38 Billion INR | 83.522% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -227.35% |
| Medico Remedies Limited | 78.67 Million INR | -3960.039% |
| Morepen Laboratories Limited | -231.17 Million INR | 1481.78% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 48.121% |
| Orchid Pharma Limited | -1.31 Billion INR | 343.127% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 236.044% |
| RPG Life Sciences Limited | -364.7 Million INR | 975.875% |
| Sigachi Industries Limited | 859.94 Million INR | -271.454% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 104.408% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2103.342% |
| Themis Medicare Limited | 764.96 Million INR | -317.579% |
| Vaishali Pharma Limited | 119.13 Million INR | -2581.258% |
| Venus Remedies Limited | -267.7 Million INR | 1293.245% |
| Windlas Biotech Limited | -273.04 Million INR | 1269.908% |
| ZIM Laboratories Limited | 983.6 Million INR | -224.756% |
| Sakar Healthcare Limited | 790.93 Million INR | -303.865% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 13.51% |
| Divi's Laboratories Limited | -39.77 Billion INR | 108.032% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 163.728% |
| Mankind Pharma Limited | -1.74 Billion INR | 282.705% |
| Sequent Scientific Limited | 4.17 Billion INR | 23.556% |
| Laurus Labs Limited | 24.35 Billion INR | 86.886% |
| Neuland Laboratories Limited | -214.05 Million INR | 1592.267% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -13.225% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 174.542% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 18.346% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1383.931% |
| Wockhardt Limited | 18.27 Billion INR | 82.516% |
| Bal Pharma Limited | 1.26 Billion INR | -152.803% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 75.263% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 375.907% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 971.481% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 157.997% |
| Shilpa Medicare Limited | 9.06 Billion INR | 64.78% |
| Valiant Laboratories Limited | 649.9 Million INR | -391.507% |
| Ajanta Pharma Limited | -954.9 Million INR | 434.518% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -973.434% |
| Granules India Limited | 9.28 Billion INR | 65.604% |
| Medicamen Biotech Limited | 160.31 Million INR | -1892.513% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -6812.46% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.35% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 89.964% |
| NATCO Pharma Limited | -5.81 Billion INR | 154.913% |
| Suven Life Sciences Limited | -1.63 Billion INR | 295.647% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -65.259% |
| Strides Pharma Science Limited | 23.25 Billion INR | 86.265% |
| Indoco Remedies Limited | 6.47 Billion INR | 50.677% |
| Alpa Laboratories Limited | 35.36 Million INR | -8932.936% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1452.154% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 439.171% |